Literature DB >> 12975269

Comparison of lacrimal and salivary gland involvement in Sjögren's syndrome.

Arjan Vissink1, Wouter W I Kalk, Khaled Mansour, Fred K L Spijkervet, Hendrika Bootsma, Jan L N Roodenburg, Cees G M Kallenberg, Arie V Nieuw Amerongen.   

Abstract

OBJECTIVES: To determine the performance of different tear and salivary tests applied in Sjögren's syndrome (SS) and to disclose how these tests relate to common serologic tests in SS.
DESIGN: In addition to the routine ocular and oral tests for diagnosing SS (Schirmer test, rose bengal score, unstimulated whole saliva flow, and parotid sialography), tear breakup time and flow rate of glandular saliva (parotid and submandibular-sublingual [SM/SL]) were evaluated in patients referred for diagnosis of SS. Patients were categorized into primary SS, secondary SS, and non-SS groups according to the revised European classification criteria for SS.
SETTING: Referral center. PATIENTS: Referred sample of 80 consecutive patients. MAIN OUTCOME MEASURE: Correlation between ocular and salivary measures.
RESULTS: Breakup time performed insufficiently in diagnosing SS, as opposed to the rose bengal score. In patients with primary and secondary SS, a clear correlation was noted between tear and saliva quality and secretion rate, and between the rose bengal score and parotid sialography. Increased rose bengal scores also correlated significantly with hyperglobulinemia and presence of SS-B antibodies in serum, with duration of subjective eye dryness, and with decreased tear-gland function. With regard to the oral tests, whole, parotid, and SM/SL salivary flow decreased significantly with increasing duration of oral complaints, with the stimulated SM/SL flow rate showing the strongest decrease and being more specific in diagnosing SS. Also, parotid sialography was more specific in excluding patients without SS than the commonly applied diagnostic criterion of secretion of unstimulated whole saliva.
CONCLUSIONS: The rose bengal score remains the eye test of choice, as it has the highest specificity for SS. Hyperglobulinemia and especially positive serologic findings for SS-B may warrant close monitoring of the eyes, since these serum findings appear to relate to the severity of ocular surface damage. Parotid sialography and stimulated secretion of SM/SL saliva are more specific in diagnosing SS than unstimulated secretion of whole saliva.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12975269     DOI: 10.1001/archotol.129.9.966

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  6 in total

1.  The assessment of oral dryness by photographic appearance of the tongue.

Authors:  C P Bots; A V Beest; H S Brand
Journal:  Br Dent J       Date:  2014-07       Impact factor: 1.626

2.  [Autoimmune sialadenitis].

Authors:  O Guntinas-Lichius; A Vissink; S Ihrler
Journal:  HNO       Date:  2010-03       Impact factor: 1.284

Review 3.  Sjögren's syndrome in older patients: aetiology, diagnosis and management.

Authors:  Rada V Moerman; Hendrika Bootsma; Frans G M Kroese; Arjan Vissink
Journal:  Drugs Aging       Date:  2013-03       Impact factor: 3.923

4.  Regulation of mRNA caspase-8 levels by anti-nuclear autoantibodies.

Authors:  Sabrina Lisi; Margherita Sisto; Dario Lofrumento; Maria Antonia Frassanito; Simone Caprio; Maria Luisa Romano; Vincenzo Mitolo; Massimo D'Amore
Journal:  Clin Exp Med       Date:  2009-12-24       Impact factor: 3.984

5.  Potential Applications of 68Ga-PSMA-11 PET/CT in the Evaluation of Salivary Gland Uptake Function: Preliminary Observations and Comparison with 99mTcO4 - Salivary Gland Scintigraphy.

Authors:  Yanhong Zhao; Yuxiao Xia; Huipan Liu; Zi Wang; Yue Chen; Wei Zhang
Journal:  Contrast Media Mol Imaging       Date:  2020-01-11       Impact factor: 3.161

6.  Unstimulated whole saliva flow for diagnosis of primary Sjögren's syndrome: time to revisit the threshold?

Authors:  Valentin Lacombe; Carole Lacout; Pierre Lozac'h; Alaa Ghali; Aline Gury; Christian Lavigne; Geoffrey Urbanski
Journal:  Arthritis Res Ther       Date:  2020-02-24       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.